Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breath and blood test could spot lung cancer earlier, reduce false positives

NCT ID NCT07370077

Diagnosis Sponsor: Chen KeZhong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new way to screen for early lung cancer using a combination of breath analysis, blood tests, and CT scans. Researchers aim to reduce the high rate of false positives from CT scans alone. They will enroll 1,800 participants, including people with lung cancer, benign nodules, and healthy controls, to build a more accurate diagnostic model.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multi-omics diagnostic test (breath and blood analysis plus CT imaging)
What this could lead to
If successful, this could lead to a more accurate, non-invasive screening method for early lung cancer, reducing unnecessary biopsies and false alarms.
What could go wrong
This is an observational study, not a treatment trial. The new method may not prove more accurate than current CT screening, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study proposes to prospectively recruit participants with early-stage non-small cell lung cancer, benign pulmonary lesions (including tuberculosis, hamartomas, inflammatory conditions, etc.), and healthy individuals undergoing medical examinations at Peking University People's Hospital, Rongcheng County People's Hospital in Xiong'an, Tangshan Workers' Hospital, Union Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology, and the 731 Hospital of China Aerospace Science and Industry Corporation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Age \>18 years old. 2. Availability of both exhaled breath and peripheral blood samples, and raw CT image data; the collection time is within one month before biopsy or surgical resection, and the subject has not received any treatment in between. 3. Pulmonary nodular lesions identified by chest CT with a diameter \< 3 cm. 4. Pulmonary nodular lesions must be surgically resected and have complete, definitive pathological information regarding their benign or malignant nature. 5. No prior history of malignant tumors. 6. Has not received anti-tumor treatments such as radiotherapy, chemotherapy, or targeted therapy. 7. Signed informed consent. Exclusion Criteria 1. Missing clinical data or incomplete sample collection. 2. Presence or suspicion of active infection or other severe co-morbidities. 3. Abnormal liver or kidney function. 4. Indefinite or inconclusive postoperative pathological results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 10010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.